読み込み中
NASDAQHealthcareBiotechnology
最新データ
$51.22
−$3.32 · -6.09%
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
通常取引
$51.22
−$3.32 · -6.09%
日中の時刻はETです。市場データは遅延する場合があります。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日中レンジ
現在 $51.22
52週レンジ
現在 $51.22
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
55
まちまち
リスク
39
中程度のリスク
モメンタム
81
強い上昇
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
日中レンジ
現在 $51.22
52週レンジ
現在 $51.22
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 売上原価 | 24.8万 USD | — | — | — |
| 粗利益 | −24.8万 USD | — | — | — |
| 研究開発 | 7915.9万 USD | 5741.5万 USD | 2853.4万 USD | 2139.7万 USD |
| 販売・一般管理 | 1889.6万 USD | 1077.9万 USD | 677.7万 USD | 376.4万 USD |
| 営業費用 | 9805.5万 USD | 6819.4万 USD | 3531.1万 USD | 2516.1万 USD |
| 受取利息 | 1108.4万 USD | 627.2万 USD | 274.8万 USD | 37.2万 USD |
| 支払利息 | — | — | — | 37.4万 USD |
| 減価償却費と償却費 | 24.8万 USD | 24.4万 USD | 15.7万 USD | 5.6万 USD |
| 営業利益 | −9805.5万 USD | −6819.4万 USD | −3531.1万 USD | −2516.1万 USD |
| 純利益 | −8697.1万 USD | −6192.2万 USD | −3256.3万 USD | −2613.5万 USD |
会社概要が更新されました 2026年10月8日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$94.40
上昇余地（84.30%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI7011.74万0.00%2.3兆 USD0.03%$379.6-0.38%
iShares Russell 2000 ETFIWM4455.98万0.06%785.63億 USD0.19%$275.18-0.91%
Vanguard Extended Market ETFVXF1903.69万0.02%954億 USD0.05%$231.53-0.84%
iShares Russell 2000 Growth ETFIWO1584.77万0.11%142.49億 USD0.24%$350.91-1.26%
iShares Biotechnology ETFIBB1258.59万0.12%104.01億 USD0.44%$197.01-3.11%
Vanguard Russell 2000 ETFVTWO1099.18万0.06%180億 USD0.06%$111.14-0.95%
State Street SPDR S&P Pharmaceuticals ETFXPH906.83万1.86%4.62億 USD0.35%$62.25-1.05%
Schwab U.S. Small-Cap ETFSCHA884.02万0.04%216.99億 USD0.03%$32.34-0.83%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
